ZER1

Across TCGA pan-cancer cohorts, ZER1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZER1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZER1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZER1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LSCC, and GBM are the cancer types where ZER1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.934	0.250	.024	9	view →
LSCC	OS	Median	All	0.773	1.000	.029	4	view →
GBM	OS	Quartile	All	0.229	0.590	.038	2	view →
LUAD	OS	Quartile	III,IV	0.861	0.341	.011	2	view →
HNSC	DFS	Median	III,IV	1.000	0.937	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZER1–PDAC (DFS)

Open the PDAC breakdown →